Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on June 6, 2023, regarding Akebia Therapeutics, Inc. (AKBA). The filing documents the results of the Company's Annual Meeting of Stockholders, including the election of directors, approval of equity incentive plans, and ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity is not provided in this document.
Material Changes and Voting Results
The following matters were submitted to and approved by stockholders at the Annual Meeting:
- Election of Directors: Three Class III directors were elected to serve until the 2026 annual meeting: Adrian Adams, Michael Rogers, and LeAnne M. Zumwalt.
- Stock Incentive Plan: Stockholders approved the 2023 Stock Incentive Plan.
- Executive Compensation: Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers.
- Auditor Ratification: Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Voting Summary
| Proposal | Votes For | Votes Against | Abstentions |
|---|---|---|---|
| Election of Adrian Adams | 61,064,658 | 23,449,941 (Withheld) | N/A |
| Election of Michael Rogers | 64,246,561 | 20,268,038 (Withheld) | N/A |
| Election of LeAnne M. Zumwalt | 60,778,528 | 23,736,071 (Withheld) | N/A |
| 2023 Stock Incentive Plan | 61,173,115 | 22,833,112 | 508,372 |
| Executive Compensation (Advisory) | 59,695,038 | 24,230,548 | 589,013 |
| Ratification of Ernst & Young LLP | 116,535,030 | 5,158,525 | 1,383,705 |
Note: Broker non-votes totaled 38,562,661 for all proposals.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or discussions of risks and contingencies. The document is strictly limited to reporting the outcomes of the Annual Meeting and listing exhibits.
Investor Verification Checklist
- Verify the full text of the 2023 Stock Incentive Plan (Exhibit 99.1) to understand dilution potential and vesting terms.
- Review the Proxy Statement filed on April 28, 2023, for detailed biographies of the newly elected directors and the rationale for executive compensation.
- Confirm the Company's financial position and liquidity status by reviewing the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Note the significant number of votes withheld for director elections (approx. 20-23 million per director), which may indicate shareholder sentiment regarding board performance.